4-氧代-1-戊基喹啉-3-羧酸 | 875148-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氧代-1-戊基喹啉-3-羧酸
• 英文名称: 4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 3-Quinolinecarboxylic acid, 1,4-dihydro-4-oxo-1-pentyl-；4-oxo-1-pentylquinoline-3-carboxylic acid
• CAS: 875148-76-8
• 化学式: C₁₅H₁₇NO₃
• mdl: MFCD20551904
• 分子量: 259.305
• InChiKey: YFXVGLMPSZFQLX-UHFFFAOYSA-N

物化性质

• 熔点：
  135-137 °C(Solv: isopropyl ether (108-20-3))
• 沸点：
  394.8±42.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氧代-1-戊基喹啉-3-羧酸 在 四(三苯基膦)钯 氯化亚砜 、 三正丁基氢锡 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 4.0h， 以65%的产率得到4-oxo-1-pentyl-1,4-dihydroquinoline-3-carbaldehyde
  参考文献：
  名称：

  Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB₂-Selective Cannabinoid Receptor Ligands:  Consequences in Receptor Affinity and Functionality

  摘要：

  CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Thus, the development of our previously described series of 4-oxo- 1,4-dihydroquinoline-3-carboxamides was pursued with the aim to further characterize the structure-affinity and structure - functionality relationships of these derivatives. The influence of the side chain was investigated by synthesizing compounds bearing various carboxamido and keto substituents. On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivatives. The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.

  DOI：

  10.1021/jm070387h
• 作为产物：
  描述：

  4-氧代-1,4-二氢喹啉-3-羧酸 在 水 、 caesium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.17h， 生成 4-氧代-1-戊基喹啉-3-羧酸
  参考文献：
  名称：

  Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay

  摘要：

  Type-1 ryanodine receptor (RyRI) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyRI are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyRI causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyRI channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyRI channel inhibitors. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.06.076

文献信息

• [EN] NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION<br/>[FR] NOUVEAUX LIGANDS DU RÉCEPTEUR CANNOBINOÏDE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2009053799A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds of f formula (I) as cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2 ) receptor modulators, and uses thereof f or treating diseases, conditions and/or disorders modulated by a cannabinoid receptor ( such as pain, neurodegenrative disorders, eating disorders, weight loss or control, and obesity).

  本发明涉及公式（I）的化合物作为大麻素受体调节剂，特别是大麻素1（CB1）或大麻素2（CB2）受体调节剂，以及它们的用途用于治疗由大麻素受体调节的疾病、症状和/或障碍（如疼痛、神经退行性疾病、进食障碍、体重减轻或控制以及肥胖症）。
• Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB₂ Cannabinoid Receptors Agonists:  Synthesis, Pharmacological Properties and Molecular Modeling
  作者：Eric Stern、Giulio G. Muccioli、Régis Millet、Jean-François Goossens、Amaury Farce、Philippe Chavatte、Jacques H. Poupaert、Didier M. Lambert、Patrick Depreux、Jean-Pierre Hénichart

  DOI：10.1021/jm050467q

  日期：2006.1.1

  the compounds behaved as CB(2) receptor agonists. Molecular modeling studies showed that compound 30 interacts with the CB(2) receptor through a combination of hydrogen bond and aromatic/hydrophobic interactions. In conclusion, 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives constitute a new class of potent and selective CB(2) cannabinoid receptors agonists.

  最新数据表明，CB（2）大麻素受体由于其在几种生理和病理过程中的潜在功能性作用而构成了有吸引力的药物靶标。一组4-氧代-1,4-二氢喹啉-3-羧酰胺衍生物，其特征是存在其他类别的大麻素配体（如位置3的脂肪族或芳香族羧酰胺基团）和烷基所表现出的一些重要结构要求合成并分析了位置1上的或苄基，以测量它们对人CB（1）和CB（2）大麻素受体的亲和力。结果表明，这些3-甲酰胺基喹诺酮类衍生物表现出CB（2）受体选择性，特别是衍生物28-30和32R。此外，在[（35）S] -GTPgammaS结合测定中，所有化合物均表现为CB（2）受体激动剂。分子模型研究表明，化合物30通过氢键和芳香族/疏水性相互作用的组合与CB（2）受体相互作用。总之，4-oxo-1,4-dihydroquinoline-3-carboxamide衍生物构成一类新型的有效和选择性CB（2）大麻素受体激动剂。
• 一种基于喹诺酮结构的光控配体及其应用
  申请人：上海科技大学

  公开号：CN113264879B

  公开（公告）日：2023-02-10

  本发明涉及生物技术领域，特别是涉及一种新型基于喹诺酮结构的光控配体及其制备方法与应用。所述基于喹诺酮结构的光控配体或其异构体前体药物、溶剂化物、药学上可接受的盐，所述基于喹诺酮结构的光控配体的结构式为：A‑linker‑B。其中，A为跨膜域配体结构，B为光控元件；Linker为线性的、对基于喹诺酮结构的光控配体无活性的亚基。本发明将偶氮苯和喹诺酮大麻素受体骨架通过合适的linker连接，使得在光照条件下配体构型变化，进而调控大麻素受体激动状态。
• 1-Aryl-4-chinolon-3-carbonsäuren
  申请人：BAYER AG

  公开号：EP0201829A1

  公开（公告）日：1986-11-20

  Die Erfindung betrifft neue 1-Aryl-4-chinolon-3-carbonsäuren der Formel (I) in welcher X1, X2 und R die in der Beschreibung angegebene Bedeutung haben, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende antibakterielle Mittel und Futterzusatzstoffe.

  本发明涉及式 (I) 的新 1-芳基-4-喹啉酮-3-羧酸（其中 X1、X2 和 R 具有描述中给出的含义）、其制备工艺以及含有这些化合物的抗菌剂和饲料添加剂。
• NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES
  申请人：DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD.

  公开号：EP0713487B1

  公开（公告）日：2000-04-19